Comparison of intrauterine PRP versus G-CSF in RIF patients

Comparison of clinical pregnancy outcome between intrauterine injection of platelet rich plasma (PRP) and granulocyte colony stimulating factor (G-CSF) in patients with more than two failed embryo transfer cycles -clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180528039878N3

Enrollment

198

Registered

2021-05-08

Start date

2021-07-23

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Repeated implantation failure. Female infertility, unspecified

Interventions

Intervention 1: Intervention group: Intrauterine injection of PRP: Endometrial preparation will be started using estradiol (4 mg daily) and ASA. From day 6, 6 mg of estradiol will be given daily. Dep

Eligibility

Sex/Gender

Female

Age

No minimum to 41 Years

Inclusion criteria

Inclusion criteria: More than two failed cycles of top and good embryo transfer Age <41 years

Exclusion criteria

Exclusion criteria: G-CSF Contraindications, PRP Contraindications, Poor ovarian response according to Bologna criteria, PGS / PGD cycles, Genetic disorders, Ovum donor or surrogacy, Severe endometriosis, Severe male factor, No embryo transfer cycles G-CSF allergy

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy. Timepoint: Six weeks after embryo transfer. Method of measurement: Ultrasonography.;Ongoing pregnancy. Timepoint: Twelve weeks after embryo transfer. Method of measurement: Ultrasonography.	—

Secondary

Measure	Time frame
Biochemical pregnancy. Timepoint: Two weeks after embryo transfer. Method of measurement: beta-hCG measurement.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Mehrafza

Mehr Medical Institute

marzieh.mehrafza@gmail.com+98 13 3376 4270

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026